{"id":"NCT02203916","sponsor":"Takeda","briefTitle":"Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-491 in Korean Subjects With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07","primaryCompletion":"2016-01","completion":"2016-02","firstPosted":"2014-07-30","resultsPosted":"2016-12-19","lastUpdate":"2016-12-19"},"enrollment":328,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Azilsartan medoxomil","otherNames":["TAK-491"]},{"type":"DRUG","name":"Azilsartan medoxomil placebo","otherNames":[]}],"arms":[{"label":"Azilsartan Medoxomil 40 mg","type":"EXPERIMENTAL"},{"label":"Azilsartan Medoxomil 80 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil versus placebo in Korean adults with essential hypertension.","primaryOutcome":{"measure":"Change From Baseline to Week 6 in Trough Clinic Sitting Systolic Blood Pressure (SBP)","timeFrame":"Baseline and Week 6","effectByArm":[{"arm":"Placebo","deltaMin":-8.776,"sd":2.0039},{"arm":"Azilsartan Medoxomil 40 mg","deltaMin":-22.093,"sd":1.4117},{"arm":"Azilsartan Medoxomil 80 mg","deltaMin":-23.731,"sd":1.4017}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"19 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":15,"countries":["South Korea"]},"refs":{"pmids":["29445520"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":65},"commonTop":["Dizziness","Nasopharyngitis","Headache","Dyspepsia"]}}